AIP
MRSN

Ameritas Investment Partners’s Mersana Therapeutics MRSN Stock Holding History

Ameritas Investment Partners’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-396
Closed -$3.41K – 3288
2025
Q1 		$3.41K Hold
396
– – ﹤0.01% 3029
2024
Q4 		$14.2K Hold
396
– – ﹤0.01% 2780
2024
Q3 		$18.7K Hold
396
– – ﹤0.01% 2694
2024
Q2 		$19.9K Hold
396
– – ﹤0.01% 2616
2024
Q1 		$44.3K Hold
396
– – ﹤0.01% 2218
2023
Q4 		$23K Hold
396
– – ﹤0.01% 2522
2023
Q3 		$12.6K Buy
396
+113
+40% +$5.37K ﹤0.01% 2731
2023
Q2 		$23.3K Hold
283
– – ﹤0.01% 2489
2023
Q1 		$29K Hold
283
– – ﹤0.01% 2292
2022
Q4 		$46.1K Hold
283
– – ﹤0.01% 2108
2022
Q3 		$47K Buy
283
+67
+31% +$10.9K ﹤0.01% 2024
2022
Q2 		$24K Hold
216
– – ﹤0.01% 2463
2022
Q1 		$22K Hold
216
– – ﹤0.01% 2519
2021
Q4 		$34K Hold
216
– – ﹤0.01% 2372
2021
Q3 		$51K Hold
216
– – ﹤0.01% 2145
2021
Q2 		$73K Buy
216
+35
+19% +$13.3K ﹤0.01% 1932
2021
Q1 		$73K Hold
181
– – ﹤0.01% 1851
2020
Q4 		$121K Hold
181
– – 0.01% 1460
2020
Q3 		$84K Buy
181
+19
+12% +$9.6K ﹤0.01% 1543
2020
Q2 		$95K Buy
162
+42
+35% +$14.3K ﹤0.01% 1443
2020
Q1 		$18K Hold
120
– – ﹤0.01% 2238
2019
Q4 		$17K Hold
120
– – ﹤0.01% 2484
2019
Q3 		$5K Buy
120
+82
+216% +$5.96K ﹤0.01% 2934
2019
Q2 		$4K Hold
38
– – ﹤0.01% 2966
2019
Q1 		$5K Hold
38
– – ﹤0.01% 2860
2018
Q4 		$4K Hold
38
– – ﹤0.01% 2887
2018
Q3 		$9K Hold
38
– – ﹤0.01% 2865
2018
Q2 		$17K Hold
38
– – ﹤0.01% 2596
2018
Q1 		$15K Buy
38
+25
+192% +$9.87K ﹤0.01% 2557
2017
Q4 		$5K Buy
+13
New +$5.67K ﹤0.01% 2871

Other funds holding MRSN

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Ameritas Investment Partners's MRSN Position: Q2 2025 in Review

Ameritas Investment Partners sold out of Mersana Therapeutics (MRSN) in Q2 2025, closing a stake of 396 shares — an estimated $3.41K sold.

Ameritas Investment Partners first reported a position in MRSN in Q4 2017 and held it in 30 quarters. The position peaked at $121K in Q4 2020. 83 funds tracked by Wall St. Rank hold MRSN as of Q2 2025.

  • Ameritas Investment Partners reported no remaining Mersana Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Ameritas Investment Partners sold 396 Mersana Therapeutics shares in Q2 2025, an estimated $3.41K.
  • Ameritas Investment Partners first reported a position in Mersana Therapeutics in Q4 2017 and held it in 30 quarters.
  • Ameritas Investment Partners's Mersana Therapeutics position peaked at $121K in Q4 2020.
  • 83 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q2 2025.

Based on Ameritas Investment Partners's 13F filing for Q2 2025, filed 12 Aug 2025.